Good news!Recently, Antigen Rapid Detection Kit (Colloidal Gold Method) independently developed and produced by Babio (stock code: 830774) has been granted the Certificate of free sale in Vietnam and the Hague certification. Among them, the self-tested rapid test kit has been whitelisted in Germany, France and Spain respectively.
This fully demonstrates the excellent performance of Babio products and the solid trust of consumers, and will also bring a new leap for the overseas layout of Babio. At present, the epidemic situation is still severe. The nucleic acid test reagents of Babio will continue to contribute to the rapid screening of novel Coronavirus and to the epidemic prevention and control and medical and health construction in Europe, the United States and Southeast Asia.
About Babio biology
Established in 2003, Jinan Biotechnology Co., Ltd. is a high-tech enterprise specializing in the r&d, production and sales of in vitro diagnostic reagents. On May 30, 2014, the company was successfully listed on the New Third Board (stock name: B A Bio, stock code: 830774), becoming one of the earliest listed companies of in vitro diagnostic reagents after the stock expansion of the New Third Board in China. In June 2021, Babio officially entered the innovation layer of neeQ.